Discover results-proven tools and methodologies for your clinical development. Learn how to improve your trial design, data collection and clinical supply. In addition, get key information on how to improve your patient recruitment and retention. Pharma IQ is proud to provide an international, non-biased, central resource, for professionals working in clinical development to exchange ideas on best practice and share case studies on innovation within the area.
In order to examine the therapy which has been labelled as a game changing addition to oncology, earlier this month industry stakeholders met to explore the evidenced potential of immune checkpoint modulation therapies. The two day conference also saw attendees discuss and formulate tactics to scale the roadblocks encountered by the therapy. Full Article »
Ahead of the Clinical Trial Supply Europe event, Pharma IQ presents interviews filmed live at last year's CTS event. In this interview Michael Pompey talks about the daily challenges he faces as a clinical trial supply manager at Sandoz and he discusses his experience with IRT. Full Video »
For Dr Hella Kohlhof, the study of epigenetics was not love at first sight, however the potential it posesses eventually won her over. Now Dr Kohlhof is Manager of Translational Pharmacology at 4SC AG and is applying epigenetic knowledge in a phase 1 first-in-man trial. She talks to us about what role epigentics plays in cancer and how new Full Podcast »
The rising presence of clinical trials (CT) in the Asia-Pacific region is predominantly driven by the East Asian region which includes China, Japan, Korea, Taiwan and Hong Kong. Over the past decade, Korea has become a global clinical trial hub and is one of the leading clinical trial destinations in the Asian region; with approximately 80% of its CTs being multinational trials from 2001-2012. Full Column »
The transition from paper to electronic Trial Master File (TMF) system, is a significant task, which is further complicated with the varying views and opinions complicating the route to standardisation. This is partially solved by the new directives under construction alongside the EMA’s updated information providing giving insight into inspector’s reviewing behaviours and what has been examined as of late for eTMFs. These much needed points of clarification help inform pharma and biotech companies on how to best create and maintain an eTMF system. Full Whitepaper »